Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haoling H Weng

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Journal of Allergy and Clinical Immunology|November 25, 2010
Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbationEli O Meltzer, William W Busse, Sally E Wenzel, et al.
Molecular Genetics and Metabolism|April 10, 2018
Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trialCary O Harding, R Stephen Amato, Mary Stuy, et al.
American Journal of Respiratory and Critical Care Medicine|January 9, 2010
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthmaJonathan Corren, William Busse, Eli O Meltzer, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2011
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indicationsAlice B Gottlieb, Kenneth Gordon, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|June 7, 2013
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE studyBernard Combe, Bhaskar Dasgupta, Ingrid Louw, et al.
Arthritis Care & Research|May 20, 2014
Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomesBhaskar Dasgupta, Bernard Combe, Ingrid Louw, et al.
The Journal of Rheumatology|January 30, 2010
Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritisHaoling H Weng, Veena K Ranganath, Dinesh Khanna, et al.
Ebiomedicine|October 28, 2018
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trialsSoumi Gupta, Kelly Lau, Cary O Harding, et al.
Molecular Genetics and Metabolism|April 15, 2018
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)Janet Thomas, Harvey Levy, Stephen Amato, et al.
Clinical and Translational Science|May 31, 2021
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuriaYulan Qi, Gina Patel, Joshua Henshaw, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Journal of Allergy and Clinical Immunology|November 25, 2010
Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbationEli O Meltzer, William W Busse, Sally E Wenzel, et al.
Molecular Genetics and Metabolism|April 10, 2018
Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trialCary O Harding, R Stephen Amato, Mary Stuy, et al.
American Journal of Respiratory and Critical Care Medicine|January 9, 2010
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthmaJonathan Corren, William Busse, Eli O Meltzer, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2011
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indicationsAlice B Gottlieb, Kenneth Gordon, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|June 7, 2013
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE studyBernard Combe, Bhaskar Dasgupta, Ingrid Louw, et al.
Arthritis Care & Research|May 20, 2014
Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomesBhaskar Dasgupta, Bernard Combe, Ingrid Louw, et al.
The Journal of Rheumatology|January 30, 2010
Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritisHaoling H Weng, Veena K Ranganath, Dinesh Khanna, et al.
Ebiomedicine|October 28, 2018
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trialsSoumi Gupta, Kelly Lau, Cary O Harding, et al.
Molecular Genetics and Metabolism|April 15, 2018
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)Janet Thomas, Harvey Levy, Stephen Amato, et al.
Clinical and Translational Science|May 31, 2021
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuriaYulan Qi, Gina Patel, Joshua Henshaw, et al.
Pageof 3